免疫疗法联合经动脉栓塞治疗转移性黑色素瘤患者：一项回顾性队列研究。
Immunotherapy and transarterial embolization in patients with metastatic melanoma: a retrospective cohort study.
机构信息
Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, H-118, New York, NY 10065, USA.
Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065,USA.
出版信息
Immunotherapy. 2024;16(14-15):955-962. doi: 10.1080/1750743X.2024.2382665. Epub 2024 Sep 3.
To investigate how the sequence of checkpoint immunotherapy (CPI) and transarterial embolization (TAE) affects overall survival (OS) of patients with metastatic melanoma. This retrospective cohort study included 65 patients with metastatic melanoma who underwent both TAE and CPI between September 2011 and January 2022. Significantly higher OS was seen in patients who received CPI before and after embolization (22 months, 95% CI 14-NR, < 0.001) compared with only before embolization (4.5 months 95% CI, 14-NR). ≤3 hepatic metastasis ( < 0.01), more TAE procedures ( < 0.001) and CPI sequence (before and after embolization) ( < 0.001) were independent predictors of survival. Metastatic melanoma patients who underwent TAE have longer survival when CPI was sequenced both before and after embolization.
为了探究检查点免疫疗法（CPI）和经动脉栓塞术（TAE）的顺序如何影响转移性黑色素瘤患者的总生存期（OS）。本回顾性队列研究纳入了 2011 年 9 月至 2022 年 1 月期间接受 TAE 和 CPI 治疗的 65 例转移性黑色素瘤患者。与仅栓塞前（95%CI，14-NR）相比，栓塞前和栓塞后接受 CPI 的患者 OS 显著更高（22 个月，95%CI 14-NR，<0.001）。肝转移灶≤3（<0.01）、TAE 次数更多（<0.001）和 CPI 顺序（栓塞前和栓塞后）（<0.001）是生存的独立预测因素。接受 TAE 的转移性黑色素瘤患者，当 CPI 在栓塞前后均进行序贯治疗时，其生存期更长。
Zotero 插件